ArticleClinical rheumatology2025
Identification of plasma protein biomarkers for ankylosing spondylitis by integrating proteome with genome.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe relationship between circulating proteome and the risk of ankylosing spondylitis (AS) remains unclear, which presents significant potential for therapeutic interventions. Therefore, we performed a proteome-wide Mendelian randomization (MR) study, followed by colocalization analysis, to identify potential biomarkers and therapeutic targets for AS.
methodsGenetic association data for 4907 plasma proteins were obtained from a large-scale protein quantitative trait locus (pQTL) study involving 35,559 individuals. Summary-level data for AS were derived from the FinnGen study, which included 2860 cases and 270,964 controls. MR and colocalization analyses were performed to assess the associations of genetically predicted plasma protein concentrations with AS risk, and potential therapeutic targets and candidate drugs for AS were assessed through drug target prioritization.
resultsGenetically predicted concentrations of 188 plasma proteins were nominally associated with AS risk using the inverse-variance weighted method (P < 0.05). After correction for multiple comparisons, elevated levels of complement factor B (CFB) and decreased levels of trem-like transcript 2 protein (TREML2) and tapasin (TAPBP) were associated with an increased risk of AS (odds ratio [OR] = 2.99, 95% confidence interval [CI] = 1.89-4.73, P = 2.76 × 10
conclusionOur study identifies plasma protein biomarkers associated with the risk of AS, which not only enhances the understanding of the molecular mechanism underlying AS but also highlights these biomarkers as potential drug targets. Key points • Genetically predicted CFB, TREML2, and TAPBP levels were significantly associated with AS risk. • Alternative MR methods and colocalization analysis validated the genetic links of CFB and TREML2 with AS. • CFB protein had the potential to be a therapeutic target for AS.
Indexed as
Identifiers
41094299What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.